<DOC>
	<DOCNO>NCT01033487</DOCNO>
	<brief_summary>PF-03635659 develop treatment chronic obstructive pulmonary disease . This study examine safety , pharmacokinetics pharmacodynamics PF-03635659 patient Chronic Obstructive Pulmonary Disease ( COPD ) .</brief_summary>
	<brief_title>A Study To Examine The Safety , Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<criteria>Male female ( woman nonchildbearing potential ) subject age 40 80 year , inclusive diagnosis moderate COPD ( GOLD , 2007 update ) meet follow criterion GOLD stage II disease Body Mass Index ( BMI ) less 35.5 kg/m2 ; total body weight &gt; 40 kg ( 88 lb ) . Current smoker , exsmokers abstain smoke least 6 month Subjects 2 exacerbation require treatment oral steroid hospitalization treatment COPD previous year . History low respiratory tract infection significant disease instability month precede screen period screen randomization .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>PF-03635659</keyword>
	<keyword>COPD</keyword>
</DOC>